SEC Tracker
Get the app

Keros Therapeutics KROS

OrbiMed Genesis Master Fund (Shareholder) plans to sell 29,400 KROS shares, about $1.3M

Form
144
Filed
Importance
Routine
Document
Form 144
  1. Approximate sale date: Aug 13, 2024
  2. Broker: Morgan Stanley Smith Barney
  3. Shares acquired by: IPO

All of OrbiMed Genesis Master Fund's insider filings, holdings and planned sales

Form 4s that likely executed this notice (SEC Tracker's match by person, company, dates and shares):

  • Sold 29,400 shares at $44.01 on Aug 13, 2024 ยท Form 4

Written from the Form 144 on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Keros Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Zevra Therapeutics ZVRA public float $455M, Jun 30, 2025
  2. Theravance Biopharma TBPH public float $449M, Jun 30, 2025
  3. aTYR PHARMA ATYR public float $464M, Jun 30, 2025
  4. Arvinas ARVN public float $469M, Jun 30, 2025
  5. Arbutus Biopharma ABUS public float $472M, Jun 30, 2025